DrugCite
Search

LIVALO

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Livalo Adverse Events Reported to the FDA Over Time

How are Livalo adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Livalo, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Livalo is flagged as the suspect drug causing the adverse event.

Most Common Livalo Adverse Events Reported to the FDA

What are the most common Livalo adverse events reported to the FDA?

Rhabdomyolysis
105 (4.92%)
Aspartate Aminotransferase Increase...
63 (2.95%)
Blood Creatine Phosphokinase Increa...
55 (2.58%)
Alanine Aminotransferase Increased
52 (2.44%)
Myalgia
45 (2.11%)
Hepatic Function Abnormal
44 (2.06%)
Liver Disorder
34 (1.59%)
Blood Lactate Dehydrogenase Increas...
33 (1.55%)
Malaise
31 (1.45%)
Pyrexia
30 (1.41%)
Blood Alkaline Phosphatase Increase...
29 (1.36%)
Show More Show More
Gamma-glutamyltransferase Increased
27 (1.27%)
Dizziness
26 (1.22%)
Pain In Extremity
22 (1.03%)
Renal Impairment
20 (.94%)
Decreased Appetite
19 (.89%)
Dehydration
19 (.89%)
Asthenia
18 (.84%)
Back Pain
18 (.84%)
Diarrhoea
18 (.84%)
Interstitial Lung Disease
18 (.84%)
Muscular Weakness
18 (.84%)
Headache
17 (.8%)
Arthralgia
16 (.75%)
Vomiting
16 (.75%)
Fall
15 (.7%)
Muscle Spasms
15 (.7%)
Pneumonia
15 (.7%)
Rash
15 (.7%)
Chest Pain
14 (.66%)
Cardiac Failure
13 (.61%)
Dyspnoea
13 (.61%)
Gait Disturbance
13 (.61%)
Nausea
13 (.61%)
White Blood Cell Count Decreased
13 (.61%)
Abdominal Pain
12 (.56%)
Constipation
12 (.56%)
Lymphocyte Stimulation Test Positiv...
12 (.56%)
Blood Bilirubin Increased
11 (.52%)
Condition Aggravated
11 (.52%)
Abdominal Pain Upper
10 (.47%)
Blood Glucose Increased
10 (.47%)
Drug Ineffective
10 (.47%)
Hypoaesthesia
10 (.47%)
Musculoskeletal Pain
10 (.47%)
Myocardial Infarction
10 (.47%)
Nasopharyngitis
10 (.47%)
Blood Pressure Increased
9 (.42%)
Abasia
8 (.37%)
Blood Creatinine Increased
8 (.37%)
Cerebral Infarction
8 (.37%)
Fatigue
8 (.37%)
Myoglobin Blood Increased
8 (.37%)
Oedema Peripheral
8 (.37%)
Pruritus
8 (.37%)
Renal Failure Acute
8 (.37%)
Thrombocytopenia
8 (.37%)
C-reactive Protein Increased
7 (.33%)
Chromaturia
7 (.33%)
Gastric Cancer
7 (.33%)
Granulocytopenia
7 (.33%)
Haemoglobin Decreased
7 (.33%)
Hypoproteinaemia
7 (.33%)
Jaundice
7 (.33%)
Joint Swelling
7 (.33%)
Platelet Count Decreased
7 (.33%)
Septic Shock
7 (.33%)
Somnolence
7 (.33%)
Subdural Haematoma
7 (.33%)
Tremor
7 (.33%)
Activities Of Daily Living Impaired
6 (.28%)
Agranulocytosis
6 (.28%)
Blood Cholesterol Increased
6 (.28%)
Blood Creatine Phosphokinase Mb Inc...
6 (.28%)
Haemoptysis
6 (.28%)
Hyperlipidaemia
6 (.28%)
Lacunar Infarction
6 (.28%)
Oedema
6 (.28%)
Oral Candidiasis
6 (.28%)
Sepsis
6 (.28%)
Urinary Tract Infection
6 (.28%)
Viral Infection
6 (.28%)
Vision Blurred
6 (.28%)
Acidosis
5 (.23%)
Alcohol Use
5 (.23%)
Altered State Of Consciousness
5 (.23%)
Angina Pectoris
5 (.23%)
Asthma
5 (.23%)
Blood Potassium Increased
5 (.23%)
Blood Pressure Decreased
5 (.23%)
Chest Discomfort
5 (.23%)
Dysarthria
5 (.23%)
Dysphagia
5 (.23%)
Hepatic Enzyme Increased
5 (.23%)
Hepatitis
5 (.23%)
Hepatitis Acute
5 (.23%)
Herpes Zoster
5 (.23%)
Insomnia
5 (.23%)
Neuroleptic Malignant Syndrome
5 (.23%)
Pain
5 (.23%)
Pleural Effusion
5 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Livalo, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Livalo is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Livalo

What are the most common Livalo adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Livalo, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Livalo is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Livalo According to Those Reporting Adverse Events

Why are people taking Livalo, according to those reporting adverse events to the FDA?

Hyperlipidaemia
394
Hypercholesterolaemia
274
Dyslipidaemia
119
Blood Cholesterol Increased
78
Product Used For Unknown Indication
54
Drug Use For Unknown Indication
21
Show More Show More
Blood Cholesterol
20
Hypertension
17
Lipids Abnormal
16
Blood Cholesterol Abnormal
11
Low Density Lipoprotein Increased
7
Rheumatoid Arthritis
6
Cardiovascular Disorder
6
Acute Myocardial Infarction
6
Angina Pectoris
4
Hepatic Steatosis
4
Type Iia Hyperlipidaemia
4
Coronary Artery Disease
3
Type 2 Diabetes Mellitus
3
Arteriosclerosis
3
Aortic Dissection
2
Myocardial Infarction
2
Blood Triglycerides
2
Lipid Metabolism Disorder
2
Hyperuricaemia
2
Blood Triglycerides Increased
1
Lipids
1
Cardiac Disorder
1
Low Density Lipoprotein Abnormal
1
Lipids Increased
1
Osteoporosis
1
Ill-defined Disorder
1
Blood Disorder
1
Systemic Lupus Erythematosus
1
Metastatic Renal Cell Carcinoma
1
Hypertriglyceridaemia
1
Arteriosclerosis Obliterans
1

Drug Labels

LabelLabelerEffective
LivaloEli Lilly and Company01-NOV-12
LivaloKowa Pharmaceuticals America, Inc. 11-APR-13

Livalo Case Reports

What Livalo safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Livalo. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Livalo.